I-Mab Biopharma
IMAB
#9390
Rank
A$0.10 B
Marketcap
$1.29
Share price
1.46%
Change (1 day)
-52.88%
Change (1 year)

Revenue for I-Mab Biopharma (IMAB)

Revenue in 2024 (TTM): A$5.29 Million

According to I-Mab Biopharma's latest financial reports the company's current revenue (TTM ) is A$5.69 Million. In 2023 the company made a revenue of A$0.87 Million an increase over the revenue in the year 2022 that were of -A$7.4 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for I-Mab Biopharma from 2017 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) A$5.29 M504.12%
2023 A$0.87 M-111.85%
2022-A$7.4 Million-314.85%
2021A$3.44 M-94.01%
2020 A$57.5 M5798.4%
2019 A$0.97 M-46.01%
2018 A$1.8 M317.83%
2017A$0.43 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
A$0.35 M-93.70%๐Ÿ‡บ๐Ÿ‡ธ USA
A$1.12 B 19,728.62%๐Ÿ‡บ๐Ÿ‡ธ USA